Atnaujinta: 2024.07.09 02:08 (GMT+3)

GRD: Mildronate – all-time export leader between the Latvian non-food consumer goods

2005.04.01, Grindeks, RIG
Gindeks                                            01.04.2005.  

Mildronate – all-time export leader between the Latvian non-food consumer goods

Mildronate is the most marketable original product and the key product of
the goup of cardiovasculars of JSC Grindeks. Mildronate has reached
remarkable sales volumes in the pharmaceutical markets of Baltic region and
the CIS countries. This is a trademark which is recognised in a number of
states. Mildronate is the third most purchased pharmaceutical product in
Belarus and ranks in the fourth place in Ukraine.

The original product of JSC Grindeks – Mildronate has been recognised as the
most exported product in the group of major non-food consumer companies during
the contest Made in Latvia.

The selling of Mildronate composes 60% of the total Grindeks’ turnover and for
now the major export markets of Mildronate are the Baltic States, Russia, Ukraine,
Belarus, Georgia, Moldova and Azerbaijan. During the year 2004 the sales of
Mildronate taken by states were- 48,8% (Russia), 41,2 % ( CIS), 4,1 % (Latvia),
6,3% (Lithuania).

In 2006 the patent protection of the above mentioned original product of Grindeks
would come to an end, that means that the generic forms of this medicine could be
produced and offered in the market by other pharmaceutical producers. World
practice shows that in those cases the original product little by little starts
to loose its market positions, namely in decrease of the turnover approximately
by 30%.

Valdis Jākobsons, the Chairman of the Board of the JSC Grindeks shortly commented
this fact by noting that „JSC Grindeks makes great investments in clinical trials
and works hardly through the years to create a new, improved form of the Mildronate.
It is planned that the new product could appear in the market in the end of the
year 2006. It is foreseen that the new form of the original product would return
with interest the money resources lost with the end of the previous patent.

Jānis Romanovskis
Finance and Administrative director
JSC Grindeks
Tel: 7083250
E-mail: janis_romanovskis@grindeks.lv


Vertybiniai popieriai

Akcijos
Obligacijos
Fondai

Rinkos informacija

Statistika
Prekyba
Indeksai
Aukcionai

Reguliavimas

Taisyklės ir nuostatos
Priežiūra

Kaip pradėti

Įmonėms
Investuotojams
Nariams
First North sertifikuotiems PATARĖJAMS

Naujienos

Nasdaq naujienos
Emitento naujienos
Kalendorius

Apie mus

Nasdaq Baltijos rinkoje
Biurai